The 21-valent pneumococcal conjugate vaccine candidate, GBP410 (also known as SP0202), demonstrates positive safety and immunogenicity data from the Phase II study.SK bioscience and Sanofi plan to start Phase III in H1
/PRNewswire/ SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced positive.
SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, has announced today.
SEATTLE, March 23, 2023 Chinook Therapeutics, Inc. , a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today. | March 23, 2023